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The brain-gut-microbiota axis consists of several key components, the central nervous system, the neuroendocrine system, the neuroimmune system and most importantly the gut Since the term Psychobiotics was first introduced in 2012 and defined as "a live organism that, when ingested in adequate amounts, produces a health benefit in patients suffering from psychiatric illness" (Dinan, Stanton et al. 2013 ) the search for new and novel therapeutics in this area continues. The term psychobiotics has also been expanded to include prebiotics (Sarkar, Lehto et al. 2016 ) and may feasibly confer benefits to both in the patient population and the at risk population. Preclinical studies demonstrating the effects of the gut microbiome on neuroimmune, neural and hormonal pathways the suggestion is that the gut microbiota can be modulated to treat neuropsychiatric disorders, or at the very least offer adjunctive treatment options for these disorders (Cryan and Dinan 2015, ).
Although much has been made of stress related psychiatric disorders, such as depression and anxiety, as the exploration of the complex and not fully discovered relationship between the brain-gut-microbiota axis continues, there is enormous scope for psychobiotics as therapeutics in patients suffering from a wide variety of psychiatric illnesses.
In the search for psychobiotics, previous studies have focussed on strains of bacteria secreting gamma-aminobutyric acid (GABA), tryptophan and short chain fatty acids (SCFAs) or impacting the hypothalamic-pituitary-adrenal axis (HPA) and the inflammatory response pathway (Jokela, Hamer et al. 2014 ). All of these parameters have shown anomalies in stress and especially in depression and anxiety disorders.
How do we identify a beneficial bacterium for neuropsychiatry treatment? How do we set out to discover potential new psychobiotics? In this review we discuss the attributes of known psychobiotics and the features which provide benefits for hosts. We discuss how these benefits are known to affect the brain-gut-microbiota axis. If new putative psychobiotics are identified how can we know which might work and allow us to focus only on trials most likely to succeed? Here we propose a strategy for the identification of novel psychobiotics.
Brain-gut-microbiota axis abnormalities in depression and related disorders
Depression is an intricate mood disorder affecting 121 million people worldwide. WHO predicts an increase to elevate depressive disorders second only to cardiovascular disease by 2020 in terms of total disease burden worldwide. Depression is often reoccurring, frequently has comorbidity with anxiety and is associated with significant disability worldwide (Kelly, have recently shown a significant reduction in microbiota richness and diversity in those suffering with depression. Furthermore, transferring the altered gut microbiota to germ-free rats induced a depressed-phenotype in these rats. This study suggests that the gut microbiota may play a causal role in depression pathophysiology.
Genomic identification of psychobiotics
The to take into account all "omic" interactions, in an attempt to evaluate the microbiome at a multi-omic, multi-system level, rather than evaluating all aspects individually. This framework may allow for better understanding of all factors affecting the microbiome and the complex multidimensional interactions at play. It is likely that the genomics of both the host, the composites of the microbiome, and the proteomic and metabolomic composition will also have a significant role in furthering our understanding of disease states.
Anti-inflammatory action and immune response and its role in Psychobiotic identification
The have shown that transferring the microbiota from stress-sensitive mice strains to non-anxious mice strains, can alter phenotype and reduce exploratory behaviours inferring increased anxiety in the recipient mice.
Testing of potential psychobiotics using rodent behavioural tests is an important step in psychobiotic identification.
Prebiotics, "Polybiotics" & Synbiotics as Psychobiotics
Prebiotics have been defined as "a non-digestible food ingredient that beneficially affects the There may too be a role for multi-strain probiotics or cocktails for pro and prebiotics to be administered in order to confer less transient and more long term benefits. There is as yet no consensus on whether psychobiotic potential is achieved best with a single strain probiotic, a multi-strain "polybiotic" or as a synbiotics, a prebiotic co-administered with probiotic.
Discussion
Determining the preclinical markers that best identify psychobiotics that will benefit patients with depression and related disorders is a major challenge. Only by adequate preclinical evaluation coupled with good clinical studies will effective algorithms emerge for identifying likely psychobiotics. Not all prebiotic, probiotic or synbiotics will have psychobiotic potential, and not all that show preclinical promise will be suitable for further development.
In investigating and developing psychobiotics it is important to focus on those strains that will alter the best "prescribed" probiotic required to address the individual's anxiety or depression. Presently however, the priority lies in identifying generic psychobiotics beneficial to many patients, prior to individualisation becoming a reality.
As research continues the more fundamental the gut microbiota appears to be in affecting the entire system, at almost all conceivable levels. In order to confer the most benefit from potential psychobiotics and develop future therapeutics continuing to evaluate the manner in which they are altering the gut microbiota is of upmost importance. The ability of potential psychobiotics to act on the areas outlined here will allow researchers to target trials on probiotics, probiotic formulations, prebiotics or synbiotics showing preclinical promise and avoid wasting valuable cost and time on unlikely candidates. A targeted and predictive approach may, hopefully, allow the development of psychobiotics in a timely fashion. Comparison between a healthy gut brain system and an abnormal system. In negative affective states such as stress anxiety or depression, pro-inflammatory markers increase, gut microbiota and gut permeability is altered and the gut brain axis is in a state of dysbosis.
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